These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16776743)

  • 1. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
    Wyne KL
    Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE; Jabbour SA; Goldstein BJ
    Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential cardiovascular benefits of insulin sensitizers.
    Kunhiraman BP; Jawa A; Fonseca VA
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.
    Dandona P; Ghanim H; Chaudhuri A; Mohanty P
    J Diabetes Complications; 2008; 22(1):62-75. PubMed ID: 18191079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic syndrome - an ongoing story.
    Duvnjak L; Duvnjak M
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():19-24. PubMed ID: 20388942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis.
    Tkác I
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S2-9. PubMed ID: 15955370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome and the menopause.
    Kaaja RJ
    Menopause Int; 2008 Mar; 14(1):21-5. PubMed ID: 18380957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women.
    Gaspard U
    Maturitas; 2009 Apr; 62(4):362-5. PubMed ID: 19131194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC; Schmieder R
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
    Wilding J
    Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
    Zarich SW
    Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.